Zur Kurzanzeige

2021-06-27Zeitschriftenartikel
State of Medical Mycology at German Academic Medical Centres: A Survey of the German-Speaking Mycological Society (DMYKG) and the Paul-Ehrlich-Society for Chemotherapy (PEG)
dc.contributor.authorGroll, Andreas H.
dc.contributor.authorGordon, Kathrin
dc.contributor.authorBuchheidt, Dieter
dc.contributor.authorWillinger, Birgit
dc.contributor.authorHeinz, Werner J.
dc.contributor.authorKurzai, Oliver
dc.contributor.authorRickerts, Volker
dc.contributor.authorCornely, Oliver A.
dc.contributor.authorthe Medical Mycology at German Academic Medical Centers (MMGAMC) Study Group
dc.date.accessioned2024-08-13T14:30:08Z
dc.date.available2024-08-13T14:30:08Z
dc.date.issued2021-06-27none
dc.identifier.other10.1111/myc.13346
dc.identifier.urihttp://edoc.rki.de/176904/11906
dc.description.abstractBackground Little is known about the infrastructure to translate advances in the management of patients at risk to develop invasive opportunistic fungal diseases. To assess the current state of Medical Mycology support in Germany, we conducted a survey among all 36 academic medical centres. Methods The survey consisted of a 3-pages questionnaire sent out in the first half of 2019. Information included details of infrastructure, education and teaching; consultation services and interdisciplinary conferences; research activities and participation in network groups; radiology, microbiology and pharmacology support; publication activity; and European Confederation for Medical Mycology (ECMM) Excellence Center designation, if assigned. Results Information was returned from 24 centres (67%). Thirteen institutions (54%) reported an independent infectious disease, and two a separate Medical Mycology department (8%); a Medical Mycology working group was reported for nine institutions (38%). An infectious disease consultation service was existent in 16 institutions (67%) and a multidisciplinary conference in 13 (54%). Fifteen institutions reported a separate study office with activities in infectious disease studies (63%). Laboratory capability for fungal identification and susceptibility testing was confirmed by all 24 institutions; testing of galactomannan by 23 (96%), cryptococcal antigen by 21 (88%), ß-D-Glucan by 9 (38%), and panfungal and Pneumocystis PCR by 21 and 22 (88% and 92%), respectively. Therapeutic drug monitoring of voriconazole was reported to be available in 15 (63%) institutions with a turnaround of ≤24 h during weekdays in 10 (42%). Two of the 24 University hospitals (8%) reported ECMM Diamond Excellence Status. Conclusions The results of this survey document the continuing need to improve the availability of specialised Medical Mycology support in German academic medical centres.eng
dc.language.isoengnone
dc.publisherRobert Koch-Institut
dc.rights(CC BY-NC-SA 3.0 DE) Namensnennung - Nicht-kommerziell - Weitergabe unter gleichen Bedingungen 3.0 Deutschlandger
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/3.0/de/
dc.subjectinfectionseng
dc.subjectmycoseseng
dc.subjectpatient careeng
dc.subjectresearcheng
dc.subjectteachingeng
dc.subject.ddc610 Medizin und Gesundheitnone
dc.titleState of Medical Mycology at German Academic Medical Centres: A Survey of the German-Speaking Mycological Society (DMYKG) and the Paul-Ehrlich-Society for Chemotherapy (PEG)none
dc.typearticle
dc.identifier.urnurn:nbn:de:0257-176904/11906-8
dc.type.versionpublishedVersionnone
local.edoc.container-titleMycosesnone
local.edoc.container-issn1439-0507none
local.edoc.pages6none
local.edoc.type-nameZeitschriftenartikel
local.edoc.container-typeperiodical
local.edoc.container-type-nameZeitschrift
local.edoc.container-urlhttps://onlinelibrary.wiley.com/journal/14390507none
local.edoc.container-publisher-nameJohn Wiley & Sons, Incnone
local.edoc.container-reportyear2021none
dc.description.versionPeer Reviewednone

Zur Kurzanzeige